Jim Miller is president of PharmSource Information Services, Inc., and publisher of Bio/Pharmaceutical Outsourcing Report.

Jim Miller

Articles

Despite investors' strong interest in the chemical industry overall, pharmaceutical chemical businesses have not experienced much attention from investors thus far.

Investors Shy Away from Pharmaceutical Chemicals

It's not clear whether contract service providers can deliver the performance improvements and costs savings that drug companies expect from large, long-term, semi-exclusive contracts.

Will CROs Take On the Risks of Strategic Outsourcing?

Sponsors who have been lax in performing financial due diligence on their contractors have been given a wake-up call by the recent developments at aaiPharma.

aaiPharma Situation Underscores The Need for Due Diligence

Recent events in the pharmaceutical outsourcing industry highlight the importance of ongoing attention to contractors' financial situations and their strategic intent.

Spotlight on Business Risk

As outsourcing services become a more integral part of pharmaceutical processes, drug companies are taking a harder line on consequential.

Stakes Getting Higher for Contractors

The changing fundamentals of the industry are causing Big Pharma to focus more on operating efficiency instead of just product performance.